Jeff Liter's profile

Jeff Liter

CEO & Founder

Luminary Therapeutics

I'm working on

2 years ago

Targeting the TME of Solid Tumors with Novel γδ CAR T Vaccine

About

Luminary Therapeutics a clinical stage Allogeneic cell therapy company with three Phase I trials cleared by the FDA is transforming single antigen cell therapies in the autoimmune and solid tumor arenas with novel target and elegant engineered signaling pathways.

Partnering listings

Learn more

Luminary Therapeutics

γδ CAR T-Cellular Vaccine for Solid Cancers

Luminary Therapeutics presents an innovative γδ T-cell-based CAR T-cell therapy, DACART, designed to target solid tumors. This dual-action therapy combines direct cytotoxic effects with immune system activation to enhanc...

TechnologyConceptualCompany

Jeff Liter

CEO & Founder

Luminary Therapeutics

Work experience

Luminary Therapeutics

CEO & Founder

Top industry applications

Not enough data yet.
Results may appear later and can be imperfect.

Open to opportunities in

Biochemical EngineeringBiological ComplexityBiotechnologyCell AssemblyCell BiologyCell Therapy

Last updated Oct 2024